About PVP Biologics
PVP Biologics is a Healthcare company based in San Diego (United States) founded in 2015 by Ingrid Swanson Pultz and David Baker, and was acquired by Takeda in February 2020. Novel enzyme therapeutics for celiac disease are engineered. PVP Biologics has raised $35 million across 1 funding round from investors including Takeda Pharmaceuticals. The company has 9 employees. PVP Biologics offers products and services including KumaMax. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its legal entity is PvP Biologics, Inc. Its competitors include Biogen, Kymeratx and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2015 and based in San Diego, United States, PVP Biologics operates in the biologics sector. An oral enzyme therapeutic, KumaMax, is being developed to degrade gluten proteins in the stomach. This approach targets celiac disease, an immune-mediated intestinal disorder triggered by gluten from wheat, rye, or barley. Core activities focus on advancing this treatment for safe gluten digestion in affected individuals.
- Headquarters San Diego, United States
- Employees 9
- Founders Ingrid Swanson Pultz, David Baker
- Stage Acquired
- SectorsHealthcare
- Website pvpbio.com
- Social X
- Acquired by Takeda (Feb 2020)
- Legal Name Pvp Biologics, Inc.
- Total Equity Funding$35M (USD)
in 1 rounds
- Latest Funding Round$35M (USD), Series B
Jan 2017
- Investors
- Employee Count9
- Acquired byTakeda
(Feb 2020)
Products & Services of PVP Biologics
PVP Biologics offers a comprehensive portfolio of products and services, including KumaMax.
Oral enzyme that breaks down gluten to alleviate celiac symptoms.
Funding Insights of PVP Biologics
PVP Biologics has successfully raised a total of $35M through 1 strategic funding round. The most recent funding activity was a Series B round of $35 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $35M
- Total Rounds 1
- Last Round Series B — $35M
- First Round $35M
(Jan 2017)
- Investors Count 1
All 1 funding rounds of PVP Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2017 | $35M | Series B | – | – |
1 investors in total: 1 institutional.
Investors in PVP Biologics
PVP Biologics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan |
Investor details for PVP Biologics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PVP Biologics
2 people are tracked at PVP Biologics (2 in leadership); the tracked headcount is 9.
| Name | Role | Group |
|---|---|---|
Ingrid Swanson Pultz | Co-Founder & CSO | Leadership |
David Baker | Co-Founder | Leadership |
Complete people profiles for PVP Biologics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PVP Biologics
3 dated milestones of PVP Biologics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded PVP Biologics is founded.
- Funding First funding round of $35.0M.
- Exit Acquired by Takeda.
Competitors of PVP Biologics
PVP Biologics has 3 listed competitors in our database, 3 of them funded. They include Biogen, Kymeratx and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of PVP Biologics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as PVP Biologics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pvp Biologics
Complete news archive for PVP Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PVP Biologics
PVP Biologics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
PVP Biologics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
PVP Biologics is a funded company, having raised a total of $35M across 1 funding round to date. The company's 1st funding round was a Series B of $35M, raised on Jan 2017.
PVP Biologics has 9 employees.
Founded in 2015 and based in San Diego, United States, PVP Biologics operates in the biologics sector. An oral enzyme therapeutic, KumaMax, is being developed to degrade gluten proteins in the stomach. This approach targets celiac disease, an immune-mediated intestinal disorder triggered by gluten from wheat, rye, or barley. Core activities focus on advancing this treatment for safe gluten digestion in affected individuals.
PVP Biologics's top competitors include Kymeratx, PureTech Health and Biogen.
PVP Biologics offers KumaMax.
PVP Biologics has 1 investor. Key investors include Takeda Pharmaceuticals.
PVP Biologics operates through Pvp Biologics, Inc..
Yes. PVP Biologics was acquired by Takeda in February 2020.